Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GlifloFastER
NCT07392788Not yet recruiting
- Sponsor
- CHU de Besançon
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of dapagliflozin in heart failure (HF) (2 arms), sponsored by CHU de Besançon. Primary endpoints: Organizational feasibility: Implementation of procedures at 3 months, Organizational feasibility: Patient flow assessment at 3 months and 6 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07392788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392788.